000 | 02053cam a2200517 i 4500 | ||
---|---|---|---|
999 |
_c68520 _d68520 |
||
001 | 18351360 | ||
005 | 20180301101903.0 | ||
008 | 141028s2014 enka b 001 0 eng c | ||
010 | _a 2014451468 | ||
020 | _a9781849738064 (hbk.) | ||
020 | _a1849738068 (hbk.) | ||
020 | _z9781782624202 (PDF) | ||
035 | _a(OCoLC)ocn872426059 | ||
040 | _CTUM | ||
050 | 0 | 0 |
_aRS420 _b.O77 2014 |
245 | 0 | 0 |
_aOrphan drugs and rare diseases / _cedited by David C. Pryde, Pfizer Global Research and Development, Cambridge, UK, Michael J. Palmer, Medicinal Chemistry Consultant, UK. |
260 |
_aCambridge _bRoyal Society of Chemistry _c2014 |
||
300 |
_axxii, 463 pages : _billustrations (some color) ; _c24 cm. |
||
504 | _aIncludes bibliographical references and index. | ||
650 | 0 | _aOrphan drugs. | |
650 | 0 | _aDrug development. | |
650 | 0 | _aRare diseases. | |
650 | 1 | 2 |
_aRare Diseases _xdrug therapy. |
650 | 2 | 2 | _aOrphan Drug Production. |
650 | 7 |
_aDrug development. _2fast |
|
650 | 7 |
_aOrphan drugs. _2fast |
|
650 | 7 |
_aRare diseases. _2fast |
|
650 | 7 |
_aMédicaments orphelins. _2ram |
|
700 | 1 |
_aPryde, David C., _eeditor. |
|
700 | 1 |
_aPalmer, Michael J., _eeditor. |
|
710 | 2 |
_aRoyal Society of Chemistry (Great Britain), _eissuing body. |
|
942 |
_2lcc _cBK |